Calithera Biosciences, Inc. — Cyborg Score 2/10

Strategic Profile

The company was focused on discovery and development of small molecule inhibitors targeting metabolic pathways critical to cancer cell growth, aiming to create novel therapeutic options for solid tumors and hematologic malignancies. The company has not generated any revenue.

Cyborg Score Rationale

Company is in liquidation phase with minimal market value (~$974) and no revenue generation. Stock trades at $0.0002 on OTC markets with extremely thin liquidity. No active business operations or commercialization path.

Top Insights

• Company entered formal liquidation in January 2023 after failing to advance precision oncology pipeline to commercialization
• Lead candidate telaglenastat (CB-839) and other clinical programs remain in pipeline but company now seeks asset sales rather than development
• Trading on OTC markets at minimal share price reflects company's shell status and lack of active business operations
• Historical partnerships with Pfizer, Incyte, and others provided development support but insufficient for commercial viability

Named Competitors

• Precision oncology platforms — Competing metabolic pathway inhibitor development (historical context only)

Recent Developments

• (February 2026) Stock passed 50-day moving average in light trading (100 shares)
• (January 2023) Plan of liquidation approved by company
• (Historical) Clinical collaborations established with major pharma partners including Pfizer and Incyte

Open the full interactive Calithera Biosciences, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.